LIGAND PHARMACEUTICALS INC's ticker is LGND and the CUSIP is 53220K504. A total of 259 filers reported holding LIGAND PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 3.43 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $1,616,000 | -50.1% | 15,500 | -35.1% | 0.03% | -87.8% |
| Q4 2018 | $3,239,000 | +4.7% | 23,870 | +111.8% | 0.21% | +8.7% |
| Q3 2018 | $3,094,000 | +23.7% | 11,270 | -6.6% | 0.20% | -8.0% |
| Q2 2018 | $2,501,000 | -9.1% | 12,070 | -27.5% | 0.21% | -21.7% |
| Q1 2018 | $2,750,000 | -20.9% | 16,650 | -34.4% | 0.27% | -25.1% |
| Q4 2017 | $3,478,000 | -47.5% | 25,400 | -47.8% | 0.36% | -47.7% |
| Q3 2017 | $6,631,000 | -13.8% | 48,700 | -23.2% | 0.69% | -23.7% |
| Q2 2017 | $7,697,000 | -38.6% | 63,400 | -46.5% | 0.91% | -45.6% |
| Q1 2017 | $12,546,000 | -0.8% | 118,540 | -4.8% | 1.67% | -35.5% |
| Q4 2016 | $12,653,000 | +16.0% | 124,530 | +16.5% | 2.59% | +31.5% |
| Q3 2016 | $10,908,000 | +28.8% | 106,880 | +50.5% | 1.97% | +23.7% |
| Q2 2016 | $8,472,000 | -3.3% | 71,030 | -13.2% | 1.59% | +0.3% |
| Q1 2016 | $8,763,000 | – | 81,830 | – | 1.59% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| KNOTT DAVID M | 353,041 | $36,819,000 | 14.92% |
| CARDINAL CAPITAL MANAGEMENT LLC /CT | 919,994 | $95,946,000 | 2.93% |
| Elk Creek Partners, LLC | 236,862 | $24,702,000 | 2.84% |
| Conestoga Capital Advisors, LLC | 619,653 | $64,624,000 | 1.56% |
| WOODSTOCK CORP | 71,489 | $7,456,000 | 1.21% |
| Summit Creek Advisors LLC | 70,962 | $7,401,000 | 1.16% |
| FALCON POINT CAPITAL, LLC | 8,115 | $846,000 | 1.08% |
| RICE HALL JAMES & ASSOCIATES, LLC | 302,503 | $31,548,000 | 1.07% |
| Stephens Investment Management Group LLC | 508,100 | $52,990,000 | 1.00% |
| Tygh Capital Management, Inc. | 55,672 | $5,806,000 | 0.96% |